Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediatorsSuelen da Silva Gomes Dias, Patrı́cia T. Bozza, Vinícius Cardoso Soares et al.|PLoS Pathogens|2020Cited by 321
SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytesAndré C. Ferreira, Thiago Moreno L. Souza, Jairo R. Temerozo et al.|Cell Death Discovery|2021Cited by 279
The clinically approved antiviral drug sofosbuvir inhibits Zika virus replicationCarolina Q. Sacramento, Thiago Moreno L. Souza, Gabrielle R. de Melo et al.|Scientific Reports|2017Cited by 243
Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine ProductionNatalia Fintelman‐Rodrigues, Thiago Moreno L. Souza, Carolina Q. Sacramento et al.|Antimicrobial Agents and Chemotherapy|2020Cited by 142
<i>In vitro</i> antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19Carolina Q. Sacramento, Thiago Moreno L. Souza, Natalia Fintelman‐Rodrigues et al.|Journal of Antimicrobial Chemotherapy|2021Cited by 104